Drug intelligence / Profile preview

baricitinib + dexamethasone

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Baricitinib + dexamethasone is a combination therapy that has been studied for the treatment of COVID-19. Both drugs have anti-inflammatory properties but work through different mechanisms. Baricitinib is a JAK inhibitor that blocks inflammatory cytokine signaling, while dexamethasone is a glucocorticoid that suppresses inflammatory responses. Clinical trials have compared the efficacy and safety of these drugs when used individually in combination with remdesivir, but the combination of both drugs together has shown potential for improving outcomes in hospitalized COVID-19 patients with severe disease.

Targets

JAK1 (Janus kinase 1)GR (Glucocorticoid receptor)JAK2 (Janus kinase 2)

Beyond the preview

Go deeper on baricitinib + dexamethasone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on baricitinib + dexamethasone.

Explore the full profile